Global health care giant Sonic Healthcare
(ASX:SHL), delivered significant revenue and earnings for the period ending 30 Jun 2021 (FY21), amid the Covid-19 pandemic.
Revenue grew 28 per cent from the prior year to $8.8 billion and earnings before interest, taxes, depreciation and amortisation grew 81 per cent from the prior year to $2.6 billion.
The medical laboratory company played a crucial role in combating the pandemic, whilst continuing to provide its usual essential healthcare services, with 138 million patients served in total.
Approximately 30 million Covid-19 tests were performed in 60 Sonic laboratories globally. Meanwhile, Sonic became Australia’s largest non-government Covid-19 vaccination provider.
Net profit grew 149 per cent from the prior year to $1.3 billion in FY21. Final Dividend of 55 cents per share was recorded, an increase of 4 cents, expected to be paid on 22 Sep 2021.
Sonic is not providing earnings guidance for FY22 due to Covid-19 related unpredictability.
Shares in Sonic Healthcare
(ASX:SHL) are trading 3.78 per cent lower at $41.21.
